Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meloxicam in acute UV dermatitis--a pilot study

C Bayerl1, R Pagung, E G Jung

  • 1Department of Dermatology Mannheim, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany.

Photodermatology, Photoimmunology & Photomedicine
|November 25, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Skin aging and evidence-based topical strategies].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2015
Same author

[Corrective-esthetic dermatology].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2015
Same author

[Undesirable pigmentation].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2015
Same author

[Phlebology in German departments of dermatology. An analysis on behalf of the German Society of Phlebology].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2013
Same author

[Acne therapy in pregnancy].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2013
Same author

Bony structures in facial skin.

Clinical and experimental dermatology·2008

Meloxicam, a COX-2 inhibitor, was studied for UV protection. In a small trial, it offered limited benefit, not exceeding that of older COX-1 inhibiting NSAIDs.

Area of Science:

  • Pharmacology
  • Dermatology
  • Photobiology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) exhibit varying effects on UV protection.
  • Meloxicam is a preferential cyclooxygenase-2 (COX-2) antagonist.
  • Older NSAIDs like indomethacin and acetylsalicylic acid (COX-1 specific) have reported UV protective benefits.

Purpose of the Study:

  • To investigate the UV protective potential of meloxicam.
  • To compare meloxicam's UV protection with that of COX-1 specific NSAIDs.

Main Methods:

  • A pilot, open-label study involving 10 patients.
  • Patients received UV irradiation at the minimal erythema dose (MED).
  • UV protection was evaluated with and without meloxicam (7.5 mg/day).

Related Experiment Videos

Main Results:

  • Meloxicam provided no UV protection benefit in 60% of patients.
  • A 1.3- to 3-fold UV protection was observed in 40% of patients.
  • The UV protection benefit of meloxicam did not surpass that of COX-1 inhibiting NSAIDs.

Conclusions:

  • Meloxicam's efficacy as a UV protective agent is limited.
  • Preferential COX-2 antagonists may not offer superior UV protection compared to older COX-1 inhibitors.
  • Further research is needed to fully elucidate NSAIDs' role in UV protection.